- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05657769
Preventive Care System Application Effectiveness Study on the Treatment of Diabetic Patients in Bandung
A Randomized Trial of Preventive Care System Application Effectiveness on the Treatment of Diabetic Patients in Bandung
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of the study is to compare the progression of HbA1c in diabetic patients after applying a Medwell digital application in addition to regular diabetes treatment (treatment arm) with regular diabetes treatment of diabetic subjects alone (control arm).
The primary endpoint will be measured as the difference between 3 months HbA1c relative to baseline in eligible subjects. Normally, HbA1c in each subject is expected to either stable or slightly increase overtime. In this study we are interested in measuring the difference in HbA1c 3 months post randomization. It is expected that in the experimental arm, HbA1c will slightly decrease, while in the standard arm, HbA1c will either remain the same or will slightly increase after 3 months in the study. Previous study shows that the standard deviation of the difference in HbA1c within 1 year is 0.97%.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Asep Irham, MD
- Phone Number: +62222033755
- Email: asep.irham@biofarma.co.id
Study Contact Backup
- Name: Salwa Halimatussadiy
- Phone Number: +62222033755
- Email: salwa.halimatussadiy@biofarma.co.id
Study Locations
-
-
West Java
-
Bandung, West Java, Indonesia, 40234
- Recruiting
- Immanuel Hospital
-
Contact:
- Indahwaty Indahwaty
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects are in the diabetes type 2 status (based on Perkeni standard) HbA1c is ≥6.5%
- Aged 18 - 60 years old
- Have compatible smartphone (minimum android 8 or iOS 13) and internet connection
- Receiving regular diabetes treatment
- Giving consent and commitment to participate in the study until finish
- Located in Bandung Area within the treatment period (up to 3 month after receiving the treatment)
- Subject is determined to be able to complete daily physical activities.
Exclusion Criteria:
- Pregnant (based on test pack)
- Participation in other weight loss program
- Use of other tracking application
- Having any abnormalities that affecting blood erythrocyte age defined by laboratory examination
- Have other severe diabetic complications that prevent subjects from participating in the prescribed program (Such as stroke, cardiac diseases (CHF stage III-IV), COPD or asthma with acute exacerbation and other respiratory diseases, peripheral artery disease, CKD stage 3-5) and other severe diseases that by the investigator's judgment, could not participate in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group I (Treatment)
Regular diabetes treatment with additional Medwell application and wearable device.
|
Regular diabetes treatment with additional Medwell application and wearable device.
|
Active Comparator: Group II (Control)
Regular diabetes treatment only with a diary card to record daily activities manually.
|
Regular diabetes treatment only with a diary card to record daily activities manually.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1C Changes
Time Frame: 3 months
|
Change in HbA1c from baseline to month 3 for all groups. Change in HbA1c from baseline to month 3 for all groups. Change in HbA1C from baseline to moth 3 of all group |
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the exercise
Time Frame: 3 months
|
Mean weekly frequency of exercise
|
3 months
|
Evaluate the exercise
Time Frame: 3 months
|
Proportion of exercise prescribed by physicians timely performed by subjects
|
3 months
|
Evaluate the exercise
Time Frame: 3 months
|
Mean duration of each exercise
|
3 months
|
Drug Adherence
Time Frame: 3 months
|
Proportion of administered drugs timely consumed by subjects
|
3 months
|
Anthropometry I (BMI)
Time Frame: 3 months
|
Change in the BMI after 3 months
|
3 months
|
Anthropometry II (Body Fat)
Time Frame: 3 months
|
Change in the Body Fat after 3 months
|
3 months
|
Anthropometry III (Muscle Mass)
Time Frame: 3 months
|
Change in the Muscle Mass after 3 months
|
3 months
|
Lab outcome I (Fasting glucose)
Time Frame: 3 months
|
Change in the lab measurement from baseline to month 3 for fasting glucose
|
3 months
|
Lab outcome II (2 hours post prandial glucose)
Time Frame: 3 months
|
Change in the lab measurement from baseline to month 3 for 2 hours postprandial glucose
|
3 months
|
Lab outcome III (total cholesterol)
Time Frame: 3 months
|
Change in the lab measurement from baseline to month 3 for total cholesterol
|
3 months
|
Lab outcome IV (low density lipoprotein)
Time Frame: 3 months
|
Change in the lab measurement from baseline to month 3 for low density lipoprotein
|
3 months
|
Lab outcome V (high density lipoprotein)
Time Frame: 3 months
|
Change in the lab measurement from baseline to month 3 for high density lipoprotein
|
3 months
|
Lab outcome VI (triglyceride)
Time Frame: 3 months
|
Change in the lab measurement from baseline to month 3 for triglyceride
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ratih Nursiana, RS Immanuel
- Study Director: Indahwaty Indahwaty, RS Immanuel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Medwell-01-2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy Genevois and other collaboratorsCompletedDiabetes Mellitus Type 2 - Insulin-TreatedFrance
Clinical Trials on Medwell Preventive Care Application
-
Virginia Commonwealth UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedPreventionUnited States
-
Children's Hospital of PhiladelphiaCenters for Disease Control and PreventionCompletedStress Disorders, PosttraumaticUnited States
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiCompleted
-
Unity Health TorontoCompletedPreventive Health CareCanada
-
Rijnstate HospitalRecruitingObesity | Obstructive Sleep Apnea | Bariatric Surgery CandidateNetherlands
-
University of PittsburghNational Institutes of Health (NIH); Arthritis FoundationWithdrawnSystemic Lupus ErythematosusUnited States
-
University Hospital, BordeauxCompletedRespiratory Failure | Chest InjuriesFrance
-
Glen TakslerNational Institute on Aging (NIA)RecruitingQuality of Life | Healthy Aging | Primary Prevention | Decision Support TechniquesUnited States
-
McMaster UniversityOntario Ministry of Health and Long Term CareCompleted
-
Albert Einstein College of MedicineNational Institute of Mental Health (NIMH)RecruitingCovid19 | ParentingUnited States